Andrija Rančić

Dr. Andrija Rančić

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DSDaniela Benedeto Stojanov
Daniela Benedeto Stojanov
VNVanja P. Ničković
Vanja P. Ničković
GPGordana Petrović
Gordana Petrović
ARAndrija Rančić
Andrija Rančić
IGIvan Grgov
Ivan Grgov
DSDušan Sokolović
Dušan Sokolović
Melatonin (MLT), earlier described as an effective anti-inflammatory agent, could be a beneficial adjunctive drug for sepsis treatment. This study aimed to determine the effects of MLT application in lipopolysaccharide (LPS)-induced sepsis in Wistar rats by determining the levels of liver tissue pro-inflammatory cytokines (TNF-α, IL-6) and NF-κB as well as hematological parameters indicating the state of sepsis. Additionally, an immunohistological analysis of CD14 molecule expression was conducted. Our research demonstrated that treatment with MLT prevented an LPS-induced increase in pro-inflammatory cytokines TNF-α and IL-6 and NF-κB levels, and in the neutrophil to lymphocyte ratio (NLR). On the other hand, MLT prevented a decrease in the blood lymphocyte number induced by LPS administration. Also, treatment with MLT decreased the liver tissue expression of the CD14 molecule observed after sepsis induction. In summary, in rats with LPS-induced sepsis, MLT was shown to be a significant anti-inflammatory agent with the potential to change the liver’s immunological marker expression, thus ameliorating liver function.

29 September 2025 in Cells
Verified
Journal Article
Open access
PDF file
VBVesna Brzački
Vesna Brzački
AJAndriana Jovanovic
Andriana Jovanovic
ARAndrija Rančić
Andrija Rančić
STSnezana Tesic-Rajkovic
Snezana Tesic-Rajkovic
GPGordana Petrović
Gordana Petrović
Stefan Desimir MomčilovićStefan Desimir Momčilović
Stefan Desimir Momčilović
Galectins represent a family of widely expressed lectins that have the ability to bind β-galactoside in modulating “cell-to-cell” and “cell-to-matrix” interactions in all organisms. These proteins are expressed in many inflammatory cells, such as macrophages, and depending on the inflammatory environment, they promote pro-inflammatory or anti-inflammatory responses. Galectin-3 (Gal-3) is predominantly located in the cytoplasm, but, as noted, it has also been detected in the nucleus, on the cell surface and in the extracellular environment, which indicates the multifunctionality of this molecule. It has been shown in many studies that Gal-3 is involved in immune regulation, fibrosis, and tissue remodeling, making it an important player in disorders such as inflammatory bowel disease (IBD), non-alcoholic steatohepatitis (NASH), and liver fibrosis. In IBD, this protein is associated with activation of the NLRP3 inflammasome, contributing to chronic intestinal inflammation. Also, in primary biliary cholangitis and autoimmune hepatitis, Gal-3 potentiate development of fibrosis through fibroblast-to-myofibroblast transition and extracellular matrix deposition, while in liver fibrosis, it is upregulated in hepatic stellate cells and macrophages, promoting fibrosis and inflammation. Studies show that Gal-3 inhibition reduces fibrosis and inflammation, making it a promising therapeutic target.

31 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
VBVesna Brzački
Vesna Brzački
ARAndrija Rančić
Andrija Rančić
STSnezana Tesic-Rajkovic
Snezana Tesic-Rajkovic
INIvan Nagorni
Ivan Nagorni
MSMarko Radomir Stamenković
Marko Radomir Stamenković
AVAleksandar Vukadinović
Aleksandar Vukadinović
Background and Objectives: Metabolic syndrome (MetS) is characterized by a cluster of metabolic abnormalities, including abdominal obesity, hyperglycemia, insulin resistance, dyslipidemia, and hypertension. Growing evidence suggests that these components may contribute to the development of gastrointestinal (GI) malignancies. This review aims to explore the association between MetS and GI cancers, including esophageal, gastric, pancreatic, and colorectal cancers. Materials and Methods: A narrative literature review was conducted using PubMed, incorporating 22 sources published between 1991 and 2024. Search terms included “gastrointestinal malignant tumors”, “metabolic syndrome”, “diabetes mellitus”, and “obesity”. Priority was given to large-scale studies from Europe, America, and Asia. Case reports, commentaries, and conference abstracts were excluded. Results: By analyzing the available literature data, this study determined that hyperinsulinemia (IGF-1 pathway), hyperglycemia, and obesity (>102 cm in men and >88 cm in women) are highly associated with the development of esophageal cancer (primarily with Barret’s long and short segment as precancerosis), gastric cancer (through reactive oxygen species), and both pancreatic (1.5–2.4 higher risk) and colorectal cancer (30% higher risk). Patients with a high BMI (>40 kg/m2) show a 20%- or 1.18-times greater risk of developing colorectal cancer and a 1.72-times higher risk of developing pancreatic cancer. There is not enough evidence on the specific influence of hypertriglyceridemia, low HDL cholesterol, and high blood pressure on the development of gastrointestinal malignancy. However, those three conditions have shown a low to moderate association (from 6% to 12%) with the development of colorectal cancer. Conclusions: Metabolic syndrome (MetS) is increasingly being recognized as a significant risk factor for the development and progression of gastrointestinal cancers. Key components such as obesity, hyperglycemia, insulin resistance, and type 2 diabetes mellitus appear to contribute to carcinogenesis through mechanisms involving chronic inflammation, oxidative stress, and immune dysregulation. Further research is needed to clarify the biological pathways linking MetS to gastrointestinal malignancies and to inform effective prevention strategies.

Verified
Journal Article
Open access
PDF file
STSnezana Tesic-Rajkovic
Snezana Tesic-Rajkovic
ARAndrija Rančić
Andrija Rančić
MSMarko Miroslav Stojanovic
Marko Miroslav Stojanovic
JZJelena Dragan Zivadinovic
Jelena Dragan Zivadinovic
IRIvana Ramić
Ivana Ramić
DSDušan Sokolović
Dušan Sokolović
Background: Sepsis is a leading cause of mortality in intensive care units, with liver dysfunction representing a critical determinant of poor outcome, mainly associated with excessive inflammation and oxidative stress. Lycopene, a carotenoid with potent antioxidant and anti-inflammatory properties, has been proposed as a potential therapeutic agent. This study investigated whether lycopene supplementation mitigates lipopolysaccharide-induced oxidative and inflammatory liver injury in rats. Methods: Male Wistar rats, divided into four groups, were exposed to either lipopolysaccharide or a combination of lipopolysaccharide (10 mg/kg) and lycopene (6 mg/kg). In order to assess liver damage induced by lipopolysaccharide, hepatocellular injury markers, oxidative stress indices, nitric oxide metabolism, glutathione redox status, apoptotic enzyme activity, and inflammatory mediators were assessed in serum and liver tissue. Results: Lipopolysaccharide induced marked hepatocellular damage, characterized by elevated serum liver-cell damage parameters, and liver tissue xanthine oxidase, myeloperoxidase, thiobrabituric reactive substances, protein carbonyl content, deoxyribonuclease I/II activity, nuclear factor kappa B, tumor necrosis factor-α, and interleukin-6, alongside depletion of reduced glutathione and reduced glutathione reductase and glutathione peroxidase activities. Lyc pretreatment significantly attenuated liver enzyme leakage, oxidative damage, and cytokine release while restoring reduced glutathione and glutathione reductase activity. In contrast, lycopene had limited effects on glutathione peroxidase activity, nitric oxide/inducible nitric oxide synthase signaling, and nuclear factor erythroid 2-related factor 2 expression. Conclusions: These findings demonstrate that lycopene confers partial hepatoprotection in endotoxemic rats, primarily through suppression of oxidative damage and nuclear factor kappa B-mediated inflammation. Further studies are needed to clarify tissue-specific mechanisms and optimize dosing strategies in order to increase the efficacy of this carotenoid.

23 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VBVesna Brzački
Vesna Brzački
ARAndrija Rančić
Andrija Rančić
STSnezana Tesic-Rajkovic
Snezana Tesic-Rajkovic
GPGordana Petrović
Gordana Petrović
LRLjubiša Dejan Rančić
Ljubiša Dejan Rančić
SJSvetlana Jovanović
Svetlana Jovanović
Background/Objectives: Colorectal cancer (CRC) is a major global health concern, with rising incidence across age groups. Early detection via colonoscopy and identification of precancerous polyps are crucial for prevention and improved outcomes. The objectives were to evaluate the epidemiology, anatomical distribution, morphology, and histopathology of CRC, and its association with synchronous colorectal polyps. Methods: In 2023, a retrospective study was conducted on 1973 patients undergoing colonoscopy due to symptoms like blood in the stool, changes in bowel habits, abdominal pain, weight loss, anemia, or as CRC follow-up. Complete colonoscopies were performed, and suspicious lesions were biopsied or resected for histological evaluation. Statistical analysis was performed using SPSS 11.0. Results: CRC was diagnosed in 78 patients (3.95%), with a male predominance (70.51%, p < 0.05) and a mean age of 65.1 ± 8.9 years. The most affected age group was 61–70 years (43.58%). Tumors were most commonly located in the rectum (32.05%) and sigmoid colon (26.92%). Polypoid morphology was observed in 67.95% of cases. Adenocarcinoma was the predominant histological type (93.59%), followed by mucinous adenocarcinoma (6.41%), with significant differences between right and left colon (p < 0.001). Synchronous polyps were detected in 47.43% of CRC cases, primarily adenomas (60.22%). In 37.84%, the tumor and polyp were in the same colon segment. Men had a higher rate of synchronous polyps than women (p < 0.05). Conclusions: CRC is more common in older males and typically affects the rectosigmoid region. Adenocarcinoma is the leading type. Nearly half of patients had synchronous adenomas, highlighting the importance of full colonoscopy for early CRC detection and prevention.

31 October 2025 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
LBLazar Bajić
Lazar Bajić
DSDejan Savic
Dejan Savic
NKNikola Krstic
Nikola Krstic
AAAna Andrejević
Ana Andrejević
ARAndrija Rančić
Andrija Rančić
TJTatjana Jevtović-Stoimenov
Tatjana Jevtović-Stoimenov
Multiple sclerosis (MS) is a chronic, autoimmune demyelinating disease of the central nervous system. The association of vitamin D deficiency, sun exposure, and higher incidence of multiple sclerosis has been known for long, and a number of studies have confirmed anti-inflammatory and neuroprotective properties of vitamin D. Vitamin D receptor (VDR) is responsible for most of the biological effects of vitamin D, and four VDR single nucleotide polymorphisms (SNPs)have been identified as possible risk factors in several autoimmune diseases. The aim of our study was to determine the prevalence of VDR polymorphisms―BsmI (rs1544410) and FokI (rs2228570) in multiple sclerosis patients within the Serbian population. A total of 169 participants from southeastern Serbia were enrolled in our study, 80 of whom were diagnosed with multiple sclerosis. The PCR-RFLP method was used for FokI and BsmI VDR polymorphism screening. There was a statistically significant difference in the distribution of FokI genotypes and alleles between MS patients and  control subjects (p = 0.006; p = 0.001). There was no statistically significant difference in BsmI genotypes and alleles between MS patients and healthy subjects (p = 0.140; p = 0.153). Our case-control study showed that the distribution of FokI rs2228570 polymorphism was more prevalent in patients with multiple sclerosis in the Serbian population, while there was no statistically significant difference in the distribution of BsmI rs1544410 polymorphism between patients with multiple sclerosis and controls.